Results 211 to 220 of about 92,697 (378)

Double-blind placebo-controlled randomized clinical trial of verapamil for chronic rhinosinusitis with nasal polyps [PDF]

open access: bronze, 2017
Marcel M. Miyake   +10 more
openalex   +1 more source

Acetylcholine From Solitary Chemosensory Cell, Not Neuron, Regulates Basal Cell Fate Driving Eosinophilic Chronic Rhinosinusitis With Nasal Polyps

open access: yesAllergy, EarlyView.
This study identifies that Ach levels are elevated in eCRSwNP and primarily released from SCCs rather than neurons. Ach induces epithelial remodeling in eCRSwNP by binding to M1R/M3R and activating YAP signaling in basal cells, driving basal cell hyperplasia and abnormal differentiation. Blocking M1R/M3R with TB inhibits eCRSwNP progression.
Bowen Zheng   +20 more
wiley   +1 more source

Orbital complications in allergic fungal rhinosinusitis: a case series from a tertiary center hospital experience. [PDF]

open access: yesAME Case Rep
Alabdulaal MR   +6 more
europepmc   +1 more source

Club Cells in Nasal Epithelial Repair: Insights From an IL‐13‐Induced Inflammatory Model

open access: yesAllergy, EarlyView.
Four inflammatory endotypes of CRSwNP, defined by eosinophil and neutrophil infiltration, show distinct patterns of basal, club, ciliated, and goblet cell expression in nasal epithelium. Using an ALI‐HNECs model, we demonstrate that IL‐13 impairs mucociliary function by promoting club‐to‐goblet cell differentiation while inhibiting club‐to‐ciliated ...
Zhi‐Qun Huang   +13 more
wiley   +1 more source

Autoallergy in chronic rhinosinusitis and its clinical relevance. [PDF]

open access: yesWorld Allergy Organ J
Sánchez J   +4 more
europepmc   +1 more source

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

open access: yesAllergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy